NYSE$DHR
Danaher Corp · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Danaher's Q4 2019 results reflected revenue growth and increased earnings per share.
Danaher Corporation reported a 5.5% increase in revenue to $4.9 billion for Q4 2019, with net earnings of $792.9 million, or $1.07 per diluted share. Non-GAAP adjusted diluted net earnings per share were $1.28, representing a 12.5% increase year-over-year. The company achieved 6.0% core revenue growth.
- Revenue increased by 5.5% year-over-year to $4.9 billion.
- Net earnings were $792.9 million, or $1.07 per diluted share.
- Non-GAAP adjusted diluted net earnings per share were $1.28, a 12.5% increase year-over-year.
- Core revenue growth was 6.0%.
Headline financials
Revenue & EPS history
Danaher · Revenue · Quarterly
$4.87B
Revenue by segment
Danaher · $3.72B total across 2 segments · Q4 2019
- Life Sciences$1.92B—51.5%
- Diagnostics$1.8B—48.5%
Forward guidance
The Company anticipates for the first quarter 2020, diluted net earnings per share will be in the range of $0.78 to $0.81 and non-GAAP adjusted diluted net earnings per share will be in the range of $1.06 to $1.09. For the full year 2020, the Company anticipates that diluted net earnings per share will be in the range of $3.96 to $4.06 and non-GAAP adjusted diluted net earnings per share will be $4.80 to $4.90, which assumes non-GAAP core revenue growth of approximately 5.0%.
Tailwinds
- Diluted net earnings per share for Q1 2020 are expected to be in the range of $0.78 to $0.81.
- Non-GAAP adjusted diluted net earnings per share for Q1 2020 are expected to be in the range of $1.06 to $1.09.
- Diluted net earnings per share for FY 2020 are anticipated to be in the range of $3.96 to $4.06.
- Non-GAAP adjusted diluted net earnings per share for FY 2020 are expected to be $4.80 to $4.90.
- FY 2020 guidance assumes non-GAAP core revenue growth of approximately 5.0%.
Headwinds
- Q1 and FY 2020 estimated results do not include the impact of earnings from the pending GE Biopharma acquisition.
- Uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof.
- Parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all.
- Danaher's ability to successfully integrate GE Biopharma's operations and employees with Danaher's existing business.
- Ability to realize anticipated financial, tax and operational synergies and benefits.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+0.0%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+0.3%
Avg return
30 days after
42%
31 / 73 earnings
Positive
+7.0%
Q4 2020
Best reaction
-9.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.5% | -9.0% | -12.2% | |
| Q4 2025 | -5.4% | -7.5% | -11.6% | |
| Q3 2025 | +6.1% | +7.0% | +6.6% | |
| Q2 2025 | -0.4% | +5.2% | -4.0% | |
| Q1 2025 | +3.8% | +6.6% | +1.4% | |
| Q4 2024 | -9.7% | -11.1% | -17.9% | |
| Q3 2024 | -5.9% | -9.8% | -13.6% | |
| Q2 2024 | +5.9% | +9.2% | +6.8% | |
| Q1 2024 | +6.1% | +4.4% | +10.7% | |
| Q4 2023 | +2.6% | +5.7% | +9.7% | |
| Q3 2023 | -5.6% | -7.9% | +8.5% | |
| Q2 2023 | +2.7% | +0.8% | -1.7% | |
| Q1 2023 | -8.6% | -6.9% | -9.4% | |
| Q4 2022 | -5.1% | -4.0% | -8.8% | |
| Q3 2022 | -5.2% | -2.3% | +1.1% | |
| Q2 2022 | +7.0% | +8.0% | +14.2% | |
| Q1 2022 | -5.6% | -10.5% | -10.2% | |
| Q4 2021 | +5.4% | +5.4% | +3.0% | |
| Q3 2021 | -0.5% | -2.5% | -0.2% | |
| Q2 2021 | +4.1% | +3.9% | +14.9% | |
| Q1 2021 | +6.3% | +5.6% | +3.3% | |
| Q4 2020 | +7.0% | +3.3% | -6.1% | |
| Q3 2020 | +2.7% | +5.8% | -0.3% | |
| Q2 2020 | -0.2% | +1.7% | +6.2% | |
| Q1 2020 | -0.6% | -1.7% | +5.3% | |
| Q4 2019 | -2.6% | -1.5% | -12.5% | |
| Q3 2019 | -1.9% | -0.9% | +3.5% | |
| Q2 2019 | +1.4% | +2.0% | +0.5% | |
| Q1 2019 | +1.6% | +2.3% | +5.0% | |
| Q4 2018 | +2.8% | +2.8% | +18.9% | |
| Q3 2018 | -4.4% | -7.2% | -1.7% | |
| Q2 2018 | +2.5% | +4.8% | +2.0% | |
| Q1 2018 | -1.0% | -2.2% | -1.1% | |
| Q4 2017 | -2.3% | -1.6% | -5.8% | |
| Q3 2017 | +5.5% | +5.7% | +8.4% | |
| Q2 2017 | -3.2% | -4.4% | -5.7% | |
| Q1 2017 | -5.5% | -3.6% | -5.0% | |
| Q4 2016 | +4.0% | +3.4% | +7.8% | |
| Q3 2016 | +3.9% | +2.1% | +2.4% | |
| Q2 2016 | -0.2% | +0.2% | -0.8% | |
| Q1 2016 | +1.6% | — | — | |
| Q4 2015 | -0.2% | — | — | |
| Q3 2015 | +4.2% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | +3.9% | — | — | |
| Q2 2014 | -4.3% | — | — | |
| Q1 2014 | -0.2% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q3 2013 | +4.1% | — | — | |
| Q2 2013 | +0.4% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | -1.2% | — | — | |
| Q3 2012 | -4.9% | — | — | |
| Q2 2012 | -1.9% | — | — | |
| Q1 2012 | -2.8% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | +6.4% | — | — | |
| Q2 2011 | -3.1% | — | — | |
| Q1 2011 | -2.1% | — | — | |
| Q4 2010 | +1.8% | — | — | |
| Q4 2007 | +1.8% | — | — | |
| Q3 2010 | +3.8% | — | — | |
| Q2 2010 | -4.4% | — | — | |
| Q1 2009 | +4.8% | — | — | |
| Q1 2010 | +0.4% | — | — | |
| Q4 2009 | -0.1% | — | — | |
| Q3 2009 | -0.8% | — | — | |
| Q3 2008 | -0.8% | — | — | |
| Q2 2009 | -2.4% | — | — | |
| Q2 2008 | -2.4% | — | — | |
| Q4 2008 | -2.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro